Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

News feed

X5 Group rebranded and became simply X5

10:50 X5

Yandex Bank enters the corporate lending market

10:41 YDEX

Arctic LNG 2 has reached record production figures

09:02 NVTK

Shareholders of Gazprom Neft approved dividends

Yesterday at 20:10 SIBN

Shareholders of Polyus approved dividends

Yesterday at 19:28 PLZL

Moscow Exchange summed up the results of trading in September

Yesterday at 17:36 MOEX

Shareholders of EvroTrans approved dividends

Yesterday at 17:22 EUTR

Ozon Pharmaceuticals places shares in the framework of the second stage of the SPO

Yesterday at 16:49 OZPH

Etalon received a land plot in the Kaliningrad region

Yesterday at 16:28 ETLN

VKontakte has integrated shopping into the feed with the help of shops

Yesterday at 15:45 VKCO